Nemaura Medical Inc. NMRD

Company Overview

Nemaura Medical Inc. is a medical technology company focused on the development and commercialization of non-invasive and minimally invasive wearable diagnostic and monitoring devices. The company operates primarily within the diabetes management, metabolic health, and digital health industries. Its core business centers on glucose monitoring technologies designed to reduce the need for traditional fingerstick blood testing and improve patient adherence through continuous data collection and analytics. Nemaura is publicly traded on Nasdaq under the ticker NMRD and has emphasized personalized metabolic tracking and preventative health applications alongside diabetes care.

The company’s primary products and revenue drivers include its sugarBEAT continuous glucose monitoring (CGM) platform and related digital health services. sugarBEAT is designed as a non-invasive or minimally invasive skin-adhered glucose monitoring system intended for use by people with diabetes and prediabetes. Nemaura has also expanded into metabolic wellness through its Miboko and BEATdiabetes programs, which combine wearable monitoring with behavioral coaching and data analytics. The company has evolved from an early-stage medical device developer into a broader digital health and metabolic diagnostics business, with strategic focus on scalable subscription-based health monitoring services and licensing opportunities.